A number of other research analysts have also weighed in on ACHN. Zacks Investment Research lowered Achillion Pharmaceuticals from a hold rating to a sell rating and set a $4.75 price objective on the stock. in a report on Tuesday, August 27th. BidaskClub lowered Achillion Pharmaceuticals from a hold rating to a sell rating in a report on Thursday. Four investment analysts have rated the stock with a sell rating and one has assigned a buy rating to the stock. The company has an average rating of Sell and an average target price of $3.63.
Shares of NASDAQ:ACHN opened at $3.93 on Thursday. The business’s 50-day moving average is $4.46 and its 200 day moving average is $3.27. The firm has a market capitalization of $557.38 million, a P/E ratio of -7.71 and a beta of 1.63. Achillion Pharmaceuticals has a 1 year low of $1.29 and a 1 year high of $5.03.
Hedge funds have recently made changes to their positions in the company. Bank of Montreal Can acquired a new position in shares of Achillion Pharmaceuticals in the second quarter valued at about $30,000. Paloma Partners Management Co acquired a new position in shares of Achillion Pharmaceuticals in the second quarter valued at about $74,000. Jane Street Group LLC acquired a new position in shares of Achillion Pharmaceuticals in the second quarter valued at about $78,000. BNP Paribas Arbitrage SA increased its holdings in shares of Achillion Pharmaceuticals by 934.3% in the first quarter. BNP Paribas Arbitrage SA now owns 31,444 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 28,404 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of Achillion Pharmaceuticals in the second quarter valued at about $97,000. 78.57% of the stock is currently owned by institutional investors and hedge funds.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.
Featured Story: Why do companies pay special dividends?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.